1. Home
  2. AGNT vs ESPR Comparison

AGNT vs ESPR Comparison

Compare AGNT & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AGNT

AGNT Inc. Common Stock

N/A

Current Price

$4.96

Market Cap

846.3M

Sector

Finance

ML Signal

N/A

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.17

Market Cap

816.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGNT
ESPR
Founded
N/A
2008
Country
United States
United States
Employees
1834
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
846.3M
816.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
AGNT
ESPR
Price
$4.96
$3.17
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.75
AVG Volume (30 Days)
1.5M
8.9M
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$4.51
$1.10
52 Week High
$5.79
$4.18

Technical Indicators

Market Signals
Indicator
AGNT
ESPR
Relative Strength Index (RSI) 58.53 64.61
Support Level N/A $3.16
Resistance Level $5.79 $3.18
Average True Range (ATR) 0.32 0.02
MACD 0.01 -0.01
Stochastic Oscillator 32.68 87.50

Price Performance

Historical Comparison
AGNT
ESPR

About AGNT AGNT Inc. Common Stock

AGNT Inc is a multi-model real estate platform, with brands including eXp Realty, eXp Commercial, NextHome, FrameVR.io, and SUCCESS Enterprises. The group prioritizes transparency, innovation, and long-term value for agents, franchise owners, staff, and shareholders.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: